SCHEMBL2611241

SCHEMBL2611241

CC(C)(C)c1ccc(Cn2cnc3cc(C(=O)NO)ccc3c2=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 11/20 0.66
HDAC1 Q13547 8/20 0.66
HDAC3 O15379 5/20 0.66
HDAC8 Q9BY41 5/20 0.66
HDAC2 Q92769 4/20 0.66
HDAC4 P56524 3/20 0.66
HDAC7 Q8WUI4 3/20 0.66
HDAC10 Q969S8 3/20 0.66
HDAC11 Q96DB2 3/20 0.66
HDAC9 Q9UKV0 3/20 0.66
HDAC5 Q9UQL6 3/20 0.66
SLC2A1 P11166 1/20 0.54
MMP13 P45452 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
RECQL P46063 1/20 0.47
MAPK10 P53779 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2611407 0.92 HDAC6 (0.66) HDAC6HDAC1HDAC3HDAC8HDAC2
SCHEMBL2619417 0.86 HDAC6 (0.64) HDAC6HDAC1HDAC3HDAC8HDAC2
SCHEMBL4550084 0.81 HDAC6 (0.58) HDAC6HDAC1HDAC3HDAC8HDAC2
SCHEMBL2117879 0.81 HDAC6 (0.63) HDAC6HDAC1HDAC3HDAC8HDAC2
SCHEMBL2118760 0.81 MMP13 (0.57) HDAC6HDAC1HDAC3HDAC8HDAC2
SCHEMBL2611259 0.79 HDAC6 (0.67) HDAC6HDAC1HDAC3HDAC8HDAC2
SCHEMBL2315906 0.79 HDAC6 (0.59) HDAC6HDAC1HDAC3HDAC8HDAC2
SCHEMBL15849074 0.79 HDAC6 (0.55) HDAC6HDAC1HDAC3HDAC8HDAC2
SCHEMBL2118004 0.78 HDAC6 (0.53) HDAC6HDAC1HDAC3HDAC8HDAC2
SCHEMBL10284931 0.77 HDAC6 (0.52) HDAC6HDAC1HDAC3HDAC8HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 HDAC6 1/4885HDAC1 2/4885HDAC3 5/4885
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 HDAC6 1/4885HDAC1 2/4885HDAC3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.